Fractyl Health reports strong preclinical data for gene therapy obesity candidate

Fractyl Health has revealed preclinical results for its gene therapy candidate RJVA-002, designed to encode both GIP and GLP-1 under a human insulin promoter to promote nutrient-responsive, pancreatic expression. According to the company, a single administration in a diet-induced obesity mouse model…